Amosartan
1st fixed-dose combination drug introduced in Korea
Amosartan Q
Controls Hypertension and Dyslipidemia at single treatment
Amosartan Plus
Treatment to patient not adequately controlled on agent double combo FDCs
Rosuzet
Increased efficacy due to improved lipid level control
Gugutams
A novel treatment option for ED patients accompanied by BPH
Monterizine
40% of allergic rhinitis patients accompanied by asthma , 80% of asthma patients accompanied by allergic rhinitis
Hyalrheuma injection
CE certified by SGS as a class-3 medical device
Hanmi Pharmaceutical and Merck Enter into Licensing Agreement to Develop Efinopegdutide
Sep 03, 2020
FDA Grants Fast Track Designation for Hanmi LAPSTriple Agonist
Jul 22, 2020
Athenex Presents Interim Data from Oral Paclitaxel Phase II Study in Cutaneous Angiosarcoma at ASCO20 Virtual Scientific Program
Jun 02, 2020